The Medigene Share
The Medigene share MDG1 (ISIN:DE000A1X3W00 ) is listed at the Frankfurt Stock Exchange since June 2000.
Investors & Media
Welcome to the Investor Relations and Public Relations division of Medigene AG. This is where you will find current information on a variety of subjects, including Medigene AG shares, company news, financial reports and key figures.
Latest News
Medigene reports financial & business results for the first three months of 2019
bluebird presents preclinical data of first TCR candidate from Medigene collaboration. Start clinical development 2020
financial highlights Q1 2019
€ 1.4 m
Revenue from immunotherapies stable
€ 65.5 m
Cash & cash equivalents and time deposits (as of March, 31 2019)
+28% R&D
Increase in research and development expenses to € 5.5 m for immunotherapies in Q1 2019, as planned
Events
21 - 23
May 2019
CIMT Annual Meeting
Mainz, Germany
22
May 2019
Annual General Meeting 2019
Munich, Germany
23 - 24
May 2019
The Immuno-Oncology 2019 World Congress
Barcelona, Spain
01 - 05
Jun 2019
ASCO - American Society of Clinical Oncology - Annual Meeting
Chicago, USA
02 - 05
Jun 2019
BIO International Convention
Booth 2201-3 German Pavillon
Philadelphia, USA
04 - 07
Jun 2019
Jefferies Global Healthcare Conference
New York, USA
07
Aug 2019
6-Months Report 2019
13
Nov 2019
9-Months Report 2019
Annual General Meeting 2019
The Annual General Meeting of Medigene shareholders for fiscal year 2018 will be held in German language on Wednesday, 22 May 2019 at "Haus der Bayerischen Wirtschaft", Max-Joseph-Straße 5, 80333 Munich, Germany.
Corporate Governance
Good corporate governance is the basis of our decision-making and monitoring processes. It stands for responsible and value-based leadership and control of the Company for long-term success, goal-oriented and efficient cooperation between the Executive Board and Supervisory Board, respect for the interests of our shareholders and employees, consistently transparent and responsible corporate decisions and an appropriate risk management system.
Contact person
Julia Hofmann
Senior Director, Head of Public & Investor Relations
investor(at)medigene.com
public.relations(at)medigene.com
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20
Dr. Robert Mayer
Senior Manager Public & Investor Relations
investor(at)medigene.com
public.relations(at)medigene.com
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20